We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Industry groups are warning the FDA that its draft guidance on risks versus benefits in 510(k) submissions could trigger new requirements for clinical trials that are inconsistent with the premarket notification process. Read More
A coalition of drugmakers wants to boost performance at clinical trial sites by establishing common standards for good clinical practices and skill requirements for investigators. Read More